Business context and reporting period
Addex Therapeutics Ltd. furnished this Form 6-K as a foreign private issuer for October 2026. It reports that the company issued a press release on October 2, 2026, identified as Exhibit 99.1. The supplied filing text does not include the press release itself.
Addex files annual reports on Form 20-F. Exhibit 99.1 is stated to be incorporated by reference into the company’s specified Form F-3 and Form S-8 registration statements, subject to later filings or reports.
Financial and operating metrics
The supplied text provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.
Changes, outlook, risks, and unusual items
No business developments, guidance, or outlook from the October 2 press release can be assessed because its contents are not present in the supplied text. The filing cautions that the company faces significant risks and refers investors to its 2025 Form 20-F, filed May 15, 2026, and other SEC filings. It also notes that actual results may differ materially from forward-looking statements.
Important facts to verify
- Obtain and review Exhibit 99.1, the October 2, 2026 press release, for the underlying announcement and any financial or clinical details.
- Review Addex’s 2025 Form 20-F and subsequent SEC filings for current financial condition, liquidity, and risk factors.
- Consider the stated incorporation by reference of Exhibit 99.1 into the specified registration statements.